StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP Free cash flow by Quarter

Non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M) ($M)

QuarterlyAnnual

Gilead Sciences Non-GAAP Free cash flow: $3,432M in Q2 2026, up 376.7% from a year earlier.

Latest, Q2 2026
3,432
Period ended Jun 30, 2026
Change on a year earlier
+376.7%
720 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

“|| Free cash flow (1) | $ | 3,432 | $ | 720 | $ | 5,859 | $ | 2,373”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K Selected Cash Flow Information.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M) ($M)Year on yearSource
Q2 2026Jun 30, 20263,432+376.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20262,427+46.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 20253,121+10.4%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 20253,962-5.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025720-39.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20251,653-21.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 20242,828+44.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 20244,169+155.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20241,195-45.7%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 20242,114+29.3%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 20231,954-18.1%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 20231,633-39.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 20232,199+32.5%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 20231,635+2.6%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 20222,386-21.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 20222,706-13.1%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Breakdown

What makes up non-GAAP Free cash flow

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP Free cash flow ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rel-fcf-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.